AGRiP’s Health Pool Resource Group (AHPRG) recently discussed litigation over insulin pricing and whether pools should consider participating in this multi-district suit. Members agreed there is minimal downside to joining and noted any recovery could represent a significant benefit for public entities, especially given the limited window of opportunity to pursue such claims.
The case centers on the high cost of insulin, driven by drug manufacturer and PBM pricing strategies. While some states have enacted consumer protections for insulin pricing, health pools and insurers may still have paid inflated costs under these practices.